Tedor Announces New Regional Business Development Director
Frank Sorce will be taking on the role of regional business development director for Tedor Pharma.
Tedor Pharma, a contract development and manufacturing organization based in Cumberland, RI, announced on Jan. 20, 2020 that Frank Sorce will be taking on the role of regional business development director for the company.
Prior to his new position, Sorce began his 30-year career in pharmaceutical sales at Merck Sharpe & Dohme and went on to hold senior sales leadership positions at Reliant Pharmaceuticals, Syneos Health, and UPM Pharmaceuticals, according to a company press release.
“Frank has a proven track record and we are excited to welcome him to the Tedor team as we continue to build on our 2019 successes,” said Doug Drysdale, president and CEO of Tedor.
Source: Tedor
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
